View in EDS HTML Full Text PDF Full Text

Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial.

Saved in:
Bibliographic Details
Title: Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial.
Authors: Brannagan, T. H. (AUTHOR), Wang, A. K. (AUTHOR), Coelho, T. (AUTHOR), Waddington Cruz, M. (AUTHOR), Polydefkis, M. J. (AUTHOR), Dyck, P. J. (AUTHOR), Plante‐Bordeneuve, V. (AUTHOR), Berk, J. L. (AUTHOR), Barroso, F. (AUTHOR), Merlini, G. (AUTHOR), Conceição, I. (AUTHOR), Hughes, S. G. (AUTHOR), Kwoh, J. (AUTHOR), Jung, S. W. (AUTHOR), Guthrie, S. (AUTHOR), Pollock, M. (AUTHOR), Benson, M. D. (AUTHOR), Gertz, M. (AUTHOR), Drachman, Brian (AUTHOR), Gorevic, Peter (AUTHOR)
Source: European Journal of Neurology. Aug2020, Vol. 27 Issue 8, p1374-1381. 8p. 1 Diagram, 2 Charts, 3 Graphs.
Subjects: Patient safety, Amyloidosis, Diabetic neuropathies, Neurological disorders, Peripheral nervous system
Geographic Terms: Norfolk (Va.)
Abstract: Background and purpose: Hereditary transthyretin (hATTR) amyloidosis causes progressive polyneuropathy resulting from transthyretin (TTR) amyloid deposition throughout the body, including the peripheral nerves. The efficacy and safety of inotersen, an antisense oligonucleotide inhibitor of TTR protein production, were demonstrated in the pivotal NEURO‐TTR study in patients with hATTR polyneuropathy. Here, the long‐term efficacy and safety of inotersen are assessed in an ongoing open‐label extension (OLE) study. Methods: Patients who completed NEURO‐TTR were eligible to enroll in the OLE (NCT02175004). Efficacy assessments included the modified Neuropathy Impairment Score plus seven neurophysiological tests composite score (mNIS + 7), the Norfolk Quality of Life – Diabetic Neuropathy (Norfolk QOL‐DN) questionnaire total score and the Short‐Form 36 Health Survey (SF‐36) Physical Component Summary (PCS) score. Safety and tolerability were also assessed. Results: Overall, 97% (135/139) of patients who completed NEURO‐TTR enrolled in the OLE. Patients who received inotersen for 39 cumulative months in NEURO‐TTR and the OLE continued to show benefit; patients who switched from placebo to inotersen in the OLE demonstrated improvement or stabilization of neurological disease progression by mNIS + 7, Norfolk QOL‐DN and SF‐36 PCS. No new safety concerns were identified. There was no evidence of increased risk for grade 4 thrombocytopenia or severe renal events with increased duration of inotersen exposure. Conclusion: Inotersen slowed disease progression and reduced deterioration of quality of life in patients with hATTR polyneuropathy. Early treatment with inotersen resulted in greater long‐term disease stabilization than delayed initiation. Routine platelet and renal safety monitoring were effective; no new safety signals were observed. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 144618552
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Brannagan%2C+T%2E+H%2E%22">Brannagan, T. H.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+A%2E+K%2E%22">Wang, A. K.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Coelho%2C+T%2E%22">Coelho, T.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Waddington+Cruz%2C+M%2E%22">Waddington Cruz, M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Polydefkis%2C+M%2E+J%2E%22">Polydefkis, M. J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dyck%2C+P%2E+J%2E%22">Dyck, P. J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Plante‐Bordeneuve%2C+V%2E%22">Plante‐Bordeneuve, V.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Berk%2C+J%2E+L%2E%22">Berk, J. L.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Barroso%2C+F%2E%22">Barroso, F.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Merlini%2C+G%2E%22">Merlini, G.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Conceição%2C+I%2E%22">Conceição, I.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hughes%2C+S%2E+G%2E%22">Hughes, S. G.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kwoh%2C+J%2E%22">Kwoh, J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jung%2C+S%2E+W%2E%22">Jung, S. W.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Guthrie%2C+S%2E%22">Guthrie, S.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pollock%2C+M%2E%22">Pollock, M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Benson%2C+M%2E+D%2E%22">Benson, M. D.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gertz%2C+M%2E%22">Gertz, M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Drachman%2C+Brian%22">Drachman, Brian</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gorevic%2C+Peter%22">Gorevic, Peter</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Neurology%22">European Journal of Neurology</searchLink>. Aug2020, Vol. 27 Issue 8, p1374-1381. 8p. 1 Diagram, 2 Charts, 3 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Patient+safety%22">Patient safety</searchLink><br /><searchLink fieldCode="DE" term="%22Amyloidosis%22">Amyloidosis</searchLink><br /><searchLink fieldCode="DE" term="%22Diabetic+neuropathies%22">Diabetic neuropathies</searchLink><br /><searchLink fieldCode="DE" term="%22Neurological+disorders%22">Neurological disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Peripheral+nervous+system%22">Peripheral nervous system</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Norfolk+%28Va%2E%29%22">Norfolk (Va.)</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background and purpose: Hereditary transthyretin (hATTR) amyloidosis causes progressive polyneuropathy resulting from transthyretin (TTR) amyloid deposition throughout the body, including the peripheral nerves. The efficacy and safety of inotersen, an antisense oligonucleotide inhibitor of TTR protein production, were demonstrated in the pivotal NEURO‐TTR study in patients with hATTR polyneuropathy. Here, the long‐term efficacy and safety of inotersen are assessed in an ongoing open‐label extension (OLE) study. Methods: Patients who completed NEURO‐TTR were eligible to enroll in the OLE (NCT02175004). Efficacy assessments included the modified Neuropathy Impairment Score plus seven neurophysiological tests composite score (mNIS + 7), the Norfolk Quality of Life – Diabetic Neuropathy (Norfolk QOL‐DN) questionnaire total score and the Short‐Form 36 Health Survey (SF‐36) Physical Component Summary (PCS) score. Safety and tolerability were also assessed. Results: Overall, 97% (135/139) of patients who completed NEURO‐TTR enrolled in the OLE. Patients who received inotersen for 39 cumulative months in NEURO‐TTR and the OLE continued to show benefit; patients who switched from placebo to inotersen in the OLE demonstrated improvement or stabilization of neurological disease progression by mNIS + 7, Norfolk QOL‐DN and SF‐36 PCS. No new safety concerns were identified. There was no evidence of increased risk for grade 4 thrombocytopenia or severe renal events with increased duration of inotersen exposure. Conclusion: Inotersen slowed disease progression and reduced deterioration of quality of life in patients with hATTR polyneuropathy. Early treatment with inotersen resulted in greater long‐term disease stabilization than delayed initiation. Routine platelet and renal safety monitoring were effective; no new safety signals were observed. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=144618552
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ene.14285
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 1374
    Subjects:
      – SubjectFull: Patient safety
        Type: general
      – SubjectFull: Amyloidosis
        Type: general
      – SubjectFull: Diabetic neuropathies
        Type: general
      – SubjectFull: Neurological disorders
        Type: general
      – SubjectFull: Peripheral nervous system
        Type: general
      – SubjectFull: Norfolk (Va.)
        Type: general
    Titles:
      – TitleFull: Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Brannagan, T. H.
      – PersonEntity:
          Name:
            NameFull: Wang, A. K.
      – PersonEntity:
          Name:
            NameFull: Coelho, T.
      – PersonEntity:
          Name:
            NameFull: Waddington Cruz, M.
      – PersonEntity:
          Name:
            NameFull: Polydefkis, M. J.
      – PersonEntity:
          Name:
            NameFull: Dyck, P. J.
      – PersonEntity:
          Name:
            NameFull: Plante‐Bordeneuve, V.
      – PersonEntity:
          Name:
            NameFull: Berk, J. L.
      – PersonEntity:
          Name:
            NameFull: Barroso, F.
      – PersonEntity:
          Name:
            NameFull: Merlini, G.
      – PersonEntity:
          Name:
            NameFull: Conceição, I.
      – PersonEntity:
          Name:
            NameFull: Hughes, S. G.
      – PersonEntity:
          Name:
            NameFull: Kwoh, J.
      – PersonEntity:
          Name:
            NameFull: Jung, S. W.
      – PersonEntity:
          Name:
            NameFull: Guthrie, S.
      – PersonEntity:
          Name:
            NameFull: Pollock, M.
      – PersonEntity:
          Name:
            NameFull: Benson, M. D.
      – PersonEntity:
          Name:
            NameFull: Gertz, M.
      – PersonEntity:
          Name:
            NameFull: Drachman, Brian
      – PersonEntity:
          Name:
            NameFull: Gorevic, Peter
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: Aug2020
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-print
              Value: 13515101
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: European Journal of Neurology
              Type: main
ResultId 1